Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles.

[1]  Jinjuan Wang,et al.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.

[2]  J. Teruya-Feldstein,et al.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. , 2012, Blood.

[3]  C. Yee,et al.  Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype , 2012, Proceedings of the National Academy of Sciences.

[4]  Xin-yang Wang,et al.  Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties , 2012, Journal of Cancer Research and Clinical Oncology.

[5]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[6]  M. Mansh.  Ipilimumab and Cancer Immunotherapy: A New Hope for Advanced Stage Melanoma , 2011, The Yale journal of biology and medicine.

[7]  E. Borden,et al.  Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects , 2011, Oncotarget.

[8]  M. Sznol,et al.  Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy , 2011, The Yale journal of biology and medicine.

[9]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[10]  Michael L. Dustin,et al.  New insights into the T cell synapse from single molecule techniques , 2011, Nature Reviews Immunology.

[11]  Steven A. Rosenberg,et al.  Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know , 2011, Nature Reviews Clinical Oncology.

[12]  Michael Loran Dustin,et al.  PKC-θ function at the immunological synapse: prospects for therapeutic targeting. , 2011, Trends in immunology.

[13]  K. Garber.  Beyond ipilimumab: new approaches target the immunological synapse. , 2011, Journal of the National Cancer Institute.

[14]  Darrell J Irvine,et al.  Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials. , 2011, Nano today.

[15]  P. González,et al.  Modulation of the dendritic cell-T-cell synapse to promote pathogen immunity and prevent autoimmunity. , 2011, Immunotherapy.

[16]  J. Karp,et al.  Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. , 2011, Biomaterials.

[17]  A. Trautmann,et al.  Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors , 2011, PloS one.

[18]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  J. Karp,et al.  Cell surface engineering of mesenchymal stem cells. , 2011, Methods in molecular biology.

[20]  M. Merino,et al.  T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  David C. Trudgian,et al.  T Cell Receptor (TCR)-induced Tyrosine Phosphorylation Dynamics Identifies THEMIS as a New TCR Signalosome Component , 2010, The Journal of Biological Chemistry.

[22]  T. Yokosuka,et al.  Dynamic regulation of T cell activation and co‐stimulation through TCR‐microclusters , 2010, FEBS letters.

[23]  U. Lorenz,et al.  The Protein Tyrosine Phosphatase SHP-1 Modulates the Suppressive Activity of Regulatory T Cells , 2010, The Journal of Immunology.

[24]  A. Barr.  Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. , 2010, Future medicinal chemistry.

[25]  M. Maio,et al.  The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. , 2010, Seminars in oncology.

[26]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[27]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[28]  R. Lechler,et al.  Adoptive regulatory T cell therapy: challenges in clinical transplantation , 2010, Current opinion in organ transplantation.

[29]  S. Rosenberg,et al.  Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.

[30]  Soong Ho Um,et al.  Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.

[31]  E. Borden,et al.  Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents , 2010, The Journal of Immunology.

[32]  Sudha Kumari,et al.  Protein Kinase C-θ Mediates Negative Feedback on Regulatory T Cell Function , 2010, Science.

[33]  M. Sadelain,et al.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  H. Fan,et al.  Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft‐versus‐host disease in allogeneic bone marrow transplantation , 2010, Transfusion.

[35]  I. Spendlove,et al.  The role of CD97 in regulating adaptive T-cell responses. , 2010, Advances in experimental medicine and biology.

[36]  L. Dupré,et al.  Plasticity of immunological synapses. , 2010, Current topics in microbiology and immunology.

[37]  Euiheon Chung,et al.  Secreted Gaussia Luciferase as a Biomarker for Monitoring Tumor Progression and Treatment Response of Systemic Metastases , 2009, PloS one.

[38]  J. Molldrem,et al.  LFA-1 Regulates CD8+ T Cell Activation via T Cell Receptor-mediated and LFA-1-mediated Erk1/2 Signal Pathways* , 2009, The Journal of Biological Chemistry.

[39]  Jae Hoon Kim,et al.  NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). , 2009, Biochemical and biophysical research communications.

[40]  F. Sánchez‐Madrid,et al.  Bringing up the rear: defining the roles of the uropod , 2009, Nature Reviews Molecular Cell Biology.

[41]  U. Lorenz,et al.  SHP‐1 and SHP‐2 in T cells: two phosphatases functioning at many levels , 2009, Immunological reviews.

[42]  C. Akdis,et al.  IL-10 suppresses CD2-mediated T cell activation via SHP-1. , 2009, Molecular immunology.

[43]  C. Eyers.  Universal sample preparation method for proteome analysis , 2009 .

[44]  L. Earl,et al.  CD45 Glycosylation controls T‐cell life and death , 2008, Immunology and cell biology.

[45]  B. Beutler,et al.  Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger , 2008, Proceedings of the National Academy of Sciences.

[46]  Jianzhu Chen,et al.  Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice , 2008, Proceedings of the National Academy of Sciences.

[47]  Jiang Tian,et al.  The Na-K-ATPase and calcium-signaling microdomains. , 2008, Physiology.

[48]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[49]  R. Ponce.  Adverse Consequences of Immunostimulation , 2008, Journal of immunotoxicology.

[50]  M. Sadelain,et al.  T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection , 2007, Nature Medicine.

[51]  J. Allison,et al.  Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability , 2007, Proceedings of the National Academy of Sciences.

[52]  R. Zaru,et al.  CD2 and TCR synergize for the activation of phospholipase Cgamma1/calcium pathway at the immunological synapse. , 2007, International immunology.

[53]  Alexey I Nesvizhskii,et al.  Protein identification by tandem mass spectrometry and sequence database searching. , 2007, Methods in molecular biology.

[54]  T. Gajewski,et al.  Immune suppression in the tumor microenvironment. , 2006, Journal of immunotherapy.

[55]  M. Tsurudome,et al.  Possible activation of murine T lymphocyte through CD98 is independent of interleukin 2/interleukin 2 receptor system. , 2006, Biomedical research.

[56]  P. Friedl,et al.  Tuning immune responses: diversity and adaptation of the immunological synapse , 2005, Nature Reviews Immunology.

[57]  Kwang-Hyun Cho,et al.  Cross-Linking of 4-1BB Activates TCR-Signaling Pathways in CD8+ T Lymphocytes1 , 2005, The Journal of Immunology.

[58]  Mark M Davis,et al.  Quantitative imaging of lymphocyte membrane protein reorganization and signaling. , 2005, Biophysical journal.

[59]  J. Egen,et al.  B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. , 2004, Immunity.

[60]  F. Sánchez‐Madrid,et al.  Recruitment of Transferrin Receptor to Immunological Synapse in Response to TCR Engagement1 , 2004, The Journal of Immunology.

[61]  B. Gao,et al.  MHC class I antigen presentation--recently trimmed and well presented. , 2004, Cellular & molecular immunology.

[62]  Mark M. Davis,et al.  T-cell-antigen recognition and the immunological synapse , 2003, Nature Reviews Immunology.

[63]  Jason S. Mitchell,et al.  Physical association and functional interaction between beta1 integrin and CD98 on human T lymphocytes. , 2003, Molecular immunology.

[64]  D. Zaller,et al.  Staging and resetting T cell activation in SMACs , 2002, Nature Immunology.

[65]  J. Egen,et al.  Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. , 2002, Immunity.

[66]  M. Choudhry,et al.  TGF-beta abrogates TCR-mediated signaling by upregulating tyrosine phosphatases in T cells. , 2001, Shock.

[67]  A. Lanzavecchia,et al.  T lymphocyte costimulation mediated by reorganization of membrane microdomains. , 1999, Science.

[68]  J. Bluestone,et al.  Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.

[69]  M. Sadelain,et al.  Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. , 1997, Blood.

[70]  M. Crumpton,et al.  Transferrin receptor induces tyrosine phosphorylation in T cells and is physically associated with the TCR zeta-chain. , 1995, Journal of immunology.